Under the deal, Kyowa Kirin will pay BridgeBio $100M upfront, plus royalties up to a high-20s percentage on sales of the product in Japan and potential milestone payments.

Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.

The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...